Plasma Fractionation Market Booms with 10.1% CAGR as Demand for Immunoglobulins and Albumin Surges Globally

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Plasma Fractionation Market is valued at USD 4.2 Bn in 2023, and it is expected to reach USD 8.9 Bn by the year 2031 with a CAGR of 10.1% during a forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2140

Plasma fractionation refers to the process of separating and isolating specific components from plasma-the liquid element of blood-to obtain therapeutically valuable products such as albumin, immunoglobulins, and clotting factors. These plasma-derived therapies are essential for the treatment and management of a wide range of medical conditions, particularly those involving immune deficiencies and rare disorders.

The global plasma fractionation market is experiencing robust growth, primarily driven by the expanding elderly population, which is more susceptible to chronic and rare diseases requiring plasma-based treatments. Rising demand for immunoglobulins and alpha-1 antitrypsin across various therapeutic areas is also contributing to increased market activity. The proliferation of plasma collection centers worldwide is further enhancing supply chain capacity. In addition, government-led initiatives aimed at increasing awareness of the clinical benefits of plasma-derived therapies are expected to further accelerate market expansion over the forecast period.

Prominent Players in the Plasma Fractionation Market:
• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• ADMA Biologics (US)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Hualan Bioengineering Co., Ltd. (China)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Kamada (Israel)
• Centurion Pharma (Istanbul)
• Prothya Biosolutions (Netherlands)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics
Drivers:
The increasing incidence of immunodeficiency disorders is a key factor propelling the growth of the plasma fractionation market. Globally, the rising demand for plasma-derived therapies-particularly immunoglobulins-continues to drive market expansion. In response, leading market participants are intensifying their research and development initiatives to introduce novel plasma-based treatments. Additionally, companies are strategically investing in and acquiring plasma collection centers to reinforce supply chain capabilities and maintain consistent access to raw plasma materials. The ongoing global rise in immunodeficiency conditions remains a critical factor sustaining demand for these therapies.

Challenges:
The growing adoption of recombinant therapies presents a notable challenge to the plasma fractionation industry. Recombinant products are gaining traction due to their reduced immunogenic profiles and their efficacy in prophylactic treatment settings. These therapies offer key advantages, such as longer half-life, reduced dosing requirements, and enhanced preventive care outcomes. Consequently, the increasing preference for recombinant alternatives in clinical practice is gradually limiting the market uptake of conventional plasma-derived treatments.

Regional Trends:
The Asia-Pacific region is anticipated to account for a significant portion of the plasma fractionation market, with strong growth expected during the forecast period. This upward trajectory is supported by the presence of major industry players actively engaged in the advancement and commercialization of innovative plasma-based therapies. In parallel, the North American market-particularly the United States-is positioned for continued expansion, driven by a well-established infrastructure of plasma fractionation facilities that underpins the region's production capabilities and overall market performance.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2140

Recent Developments:
• In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
• In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.

Segmentation of Plasma Fractionation Market-
By Product-
• Immune-Globulins
o Intravenous Immune-Globulins
o Subcutaneous Immune-Globulins
o Other Immune-Globulins
• Coagulation Factor Concentrates
o Factor VIII
o Factor IX
o Von Willebrand Factor
o Prothrombin Complex Concentrate
o Fibrinogen Concentrates
o Factor XIII
o Others
• Albumin
• Protease Inhibitors
• Other Plasma Products
By Application-
• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Others
By End-User-
• Hospitals & Clinics
• Clinical Research Laboratories
• Academic Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/plasma-fractionation-market/2140

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.